TY - JOUR
T1 - EFFICACY OF HALF-DOSE PHOTODYNAMIC THERAPY VERSUS HIGH-DENSITY SUBTHRESHOLD MICROPULSE LASER FOR TREATING PIGMENT EPITHELIAL DETACHMENTS IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
AU - Feenstra, Helena M. A.
AU - Hahn, Leo C.
AU - van Rijssen, Thomas J.
AU - Tsonaka, Roula
AU - Breukink, Myrte B.
AU - Keunen, Jan. E. E.
AU - Peters, Petrus J. H.
AU - Dijkman, Greet
AU - Souied, Eric H.
AU - MacLaren, Robert E.
AU - Querques, Giuseppe
AU - Downes, Susan M.
AU - Fauser, Sascha
AU - Hoyng, Carel B.
AU - van Dijk, Elon H. C.
AU - Boon, Camiel J. F.
N1 - Funding Information: H. M. A. Feenstra was supported by the Blindenhulp Fellowship from Stichting Blindenhulp (The Hague, the Netherlands).This research was also supported by the following foundations: Stichting Ooglijders (Rotterdam, the Netherlands), Stichting Macula Fonds, Retina Nederland Onderzoek Fonds, Stichting Blinden-Penning, Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Landelijke Stichting voor Blinden en Slechtzienden that contributed through UitZicht (Delft, the Netherlands), Rotterdamse Stichting Blindenbelangen (Rotterdam, the Netherlands), Stichting Leids Oogheelkundig Ondersteuningsfonds (Leiden, the Netherlands), the Oxford NIHR Biomedical Research Centre (Oxford, United Kingdom), the Gisela Thier Fellowship of Leiden University (Leiden, the Netherlands [C. J. F. Boon]), and the Netherlands Organization for Scientific Research (VENI grant to C. J. F. Boon). These funding organizations provided unrestricted grants and had no role in the design or conduct of this research. This investigator-initiated study received funding from Novartis Pharma B.V. (Arnhem, the Netherlands) solely for the purchase of verteporfin (Visudyne®) to enable half-dose photodynamic therapy treatment at the Oxford site because photodynamic therapy currently is not reimbursed routinely by the UK National Health Service for treating central serous chorioretinopathy. Novartis Pharma B.V. had no role in funding, designing, conducting, or evaluating the study, nor in the writing of this manuscript. Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Purpose:Comparing the effect of half-dose photodynamic therapy and high-density subthreshold micropulse laser treatment on retinal pigment epithelial detachments (PEDs) in chronic central serous chorioretinopathy.Methods:This study included data from the PLACE trial, a prospective randomized controlled trial comparing half-dose photodynamic therapy and high-density subthreshold micropulse laser treatment in chronic central serous chorioretinopathy. Main outcome measurements were changes in both the foveal PED and the highest PED within the macula at baseline compared with first and final evaluation visit.Results:At baseline, a macular PED was detected in 76.9% of patients (123/160), and a PED within 1,500 µm from the foveal center in 37.5% of patients (60/160). In the half-dose photodynamic therapy arm (61 patients), there was a significantly larger decrease in the highest macular PED compared with the high-density subthreshold micropulse laser treatment arm (62 patients) at both first and final evaluation visits (P < 0.001 and P = 0.012, respectively). The decrease of highest foveal PED was significant at first visit (P = 0.025).Conclusion:Half-dose photodynamic therapy is superior to high-density subthreshold micropulse laser treatment with regard to a statistically significant reduction in the height of macular PEDs in active chronic central serous chorioretinopathy. These findings may also have implications for other diseases within the pachychoroid disease spectrum that can present with PEDs.
AB - Purpose:Comparing the effect of half-dose photodynamic therapy and high-density subthreshold micropulse laser treatment on retinal pigment epithelial detachments (PEDs) in chronic central serous chorioretinopathy.Methods:This study included data from the PLACE trial, a prospective randomized controlled trial comparing half-dose photodynamic therapy and high-density subthreshold micropulse laser treatment in chronic central serous chorioretinopathy. Main outcome measurements were changes in both the foveal PED and the highest PED within the macula at baseline compared with first and final evaluation visit.Results:At baseline, a macular PED was detected in 76.9% of patients (123/160), and a PED within 1,500 µm from the foveal center in 37.5% of patients (60/160). In the half-dose photodynamic therapy arm (61 patients), there was a significantly larger decrease in the highest macular PED compared with the high-density subthreshold micropulse laser treatment arm (62 patients) at both first and final evaluation visits (P < 0.001 and P = 0.012, respectively). The decrease of highest foveal PED was significant at first visit (P = 0.025).Conclusion:Half-dose photodynamic therapy is superior to high-density subthreshold micropulse laser treatment with regard to a statistically significant reduction in the height of macular PEDs in active chronic central serous chorioretinopathy. These findings may also have implications for other diseases within the pachychoroid disease spectrum that can present with PEDs.
KW - PLACE trial
KW - central serous chorioretinopathy
KW - half-dose photodynamic therapy
KW - high-density subthreshold micropulse laser
KW - pigment epithelial detachment
UR - http://www.scopus.com/inward/record.url?scp=85128131412&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/IAE.0000000000003363
DO - https://doi.org/10.1097/IAE.0000000000003363
M3 - Article
C2 - 34864802
SN - 0275-004X
VL - 42
SP - 721
EP - 729
JO - Retina (Philadelphia, Pa.)
JF - Retina (Philadelphia, Pa.)
IS - 4
ER -